A study of the lead agent CPI-613 in a class of anti-cancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and used in combination, could have efficacy against reducing some tumors. The research, led by Paul M. Bingham, Ph.D., of the Department of Biochemistry and Cell Biology in the Renaissance School of Medicine at Stony Brook University, will help advance clinical testing of CPI-613 and similar agents that are designed to disrupt cancer cell mitochondrial metabolism, a complex process that feeds tumor growth. The findings are published in PLOS ONE.
Study of anti-cancer mitochondrial drug shows additional clinical promise
A study of the lead agent CPI-613 in a class of anti-cancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and used in combination, could have efficacy against reducing some tumors. The research, led by Paul M. Bingham, Ph.D., of the Department of Biochemistry and Cell Biology in the Renaissance School of Medicine at Stony Brook University, will help advance clinical testing of CPI-613 and similar agents that are designed to disrupt cancer cell mitochondrial metabolism, a complex process that feeds tumor growth. The findings are published in PLOS ONE.